Clinical trials: Myelosuppression
Lymphoma Nonhodgkin
Revlimid® Capsules General Drug Use-results Surveillance (Relapsed or Refractory FL and MZL)
To ascertain the safety of Revlimid® Capsules 2.5 mg or 5 mg under the actual use conditions in patients who received R2 combination therapy with the drug and rituximab for the first time for relapsed or refractory follicular…
- Trial name
- NCT04618081
- Where
- Japan
- Volunteers
- 151 people
- Sponsor
- Celgene
Tumor Patients
A Single-arm, Multi-center, Phase II Exploratory Clinical Study to Evaluate the Efficacy and Safety of Trilaciclib in Preventing Myelosuppression Caused by Topoisomerase I Inhibitor Type ADC Drugs
Evaluation of the efficacy and safety of Trilaciclib in preventing myelosuppression caused by topoisomerase I inhibitor type ADC drugs
- Trial name
- Trilaciclib (NCT07736001)
- Testing
- Trilaciclib and Topoisomerase I inhibitor type ADC drugs
- Where
- 2 sites in China
- Volunteers
- 96 people
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
Myelosuppression, Thoracic Neoplasms
Clinical Study of Thiopegfilgrastim for Preventing Bone Marrow Suppression in Thoracic Tumor Chemoradiotherapy
This is a prospective observational study designed to observe and evaluate the safety and efficacy of mecapegfilgrastim in the treatment of moderate-to-severe myelosuppression associated with concurrent chemoradiotherapy.
- Conditions
- Myelosuppression, Thoracic Neoplasms, Chemoradiotherapy
- Trial name
- ANC-IIT-004 (NCT07205536)
- Testing
- Mecapegfilgrastim injection, Oral or short-acting granulocyte-stimulating agents
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Affiliated Hospital of Nantong University
Chemotherapy-induced Neutropenia, Myelosuppression
Real World Study of PEG-rhG-CSF in Prevention of Chemotherapy-induced Neutropenia
The aim of this study is to observe and evaluate the cost-effectiveness,efficacy and safety of PEG-rhG-CSF in preventing chemotherapy-induced neutropenia(CIN) of cancer patients in the real world.1000 patients with non-myeloid…
- Trial name
- NCT03846414
- Testing
- PEG-rhG-CSF
- Volunteers
- 1,500 people
- Sponsor
- CSPC Baike (Shandong) Biopharmaceutical Co., Ltd.
Breast Cancer
Injection Regimen Trial of PEG-rhG-CSF During Breast Cancer Chemotherapy
The purpose of this study is to try to find a better injection regimen (including time and dose) of PEG-rhG-CSF, which is supposed to better prevent bone marrow suppression and/or FN in breast cancer patients who receive…
- Trial name
- NCT04477616
- Testing
- Day 7 regimen, Day 3 regimen
- Where
- China
- Volunteers
- 160 people
- Sponsor
- The First Affiliated Hospital with Nanjing Medical University
Non-Small Cell Lung Cancer, Myelosuppression
Trilaciclib in Combination With Docetaxel for Second-Line and Beyond Treatment of Locally Advanced or Metastatic NSCLC
This study is a prospective, single arm phase II study aimed at patients with locally advanced or metastatic non-small cell lung cancer undergoing second-line or beyond treatment.
- Trial name
- PROTECT-1 (NCT06929936)
- Testing
- Trilaciclib combined with Docetaxel
- Where
- China
- Volunteers
- 33 people
- Sponsor
- The First Affiliated Hospital of Xiamen University
Non-Hodgkin's Lymphoma
Doxorubicin Pharmacokinetics and Response in Non Hodgkin's Lymphoma
In previous studies, the investigators found that in patients with Hodgkin's lymphoma (HL) treated with ABVD (adriamycin, bleomycin, vinblastine and decarbazine) the absence of alopecia may predict for a poor response to…
- Trial name
- NCT00969462
- Testing
- Doxorubicin
- Where
- Israel
- Volunteers
- 18 people
- Sponsor
- Meir Medical Center
Quality of Life, Fatigue
Complementary Treatment of PG2 to Improve Clinical Benefit Response and Quality of Life in Fatigue
The objective of this study is to evaluate the efficacy and safety of PG2 as a complementary treatment to conventional chemotherapy among NSCLC patients.
- Conditions
- Quality of Life, Fatigue, Complementary
- Trial name
- NCT00518869
- Testing
- PG2
- Where
- 10 sites in Taiwan
- Volunteers
- 13 people
- Sponsor
- PhytoHealth Corporation
Extensive-stage Small-cell Lung Cancer
Evaluation of TRILACICLIB in Chinese Patients With Extensive-stage Small Cell Lung Cancer (ES-SCLC) for Chemotherapy-induced Myelosuppression, Antitumor Effects of Combination Regimens, and Safety in a Real-world Study
This is a single-arm, real-world study in Chinese patients with extensive stage small cell lung cancer. The purpose of this study was to evaluate Trilaciclib's protection against chemotherapy-induced bone marrow suppression, the…
- Trial name
- NCT05071703
- Testing
- Trilaciclib
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Jiangsu Simcere Pharmaceutical Co., Ltd.
Bone Marrow Suppression, Fever, Sweats, and Hot Flashes
Prevention of Infection in Patients With Hematologic Cancer and Persistent Fever Caused by a Low White Blood Cell Count
RATIONALE: Antibiotic therapy may prevent the development of infection in patients with hematologic cancer and the persistent fever caused by a low white blood cell count.
- Conditions
- Bone Marrow Suppression, Fever, Sweats, and Hot Flashes, Infection, Leukemia
- Trial name
- NCT00003805
- Testing
- piperacillin sodium, piperacillin-tazobactam, tazobactam sodium
- Where
- 28 sites in United States, Belgium and 11 more
- Volunteers
- 859 people
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
Brain Tumor
Electronic Medical Record Review in Monitoring the Effects of Adherence on Myelosuppression and Morbidity in Patients With Newly Diagnosed Brain Tumors Receiving Temozolomide and Radiation Therapy
This research trial studies electronic medical record review in monitoring the effects of adherence on myelosuppression and morbidity in patients with newly diagnosed brain tumors receiving temozolomide and radiation therapy.
- Trial name
- NCT02208336
- Testing
- medical chart review
- Where
- United States
- Volunteers
- 79 people
- Sponsor
- Wake Forest University Health Sciences
Inflammatory Bowel Diseases
Tailored Therapeutic Model According to the Expression of Genes in Inflammatory Bowel Disease Patients
This study is a randomized controlled study conducted at five tertiary university hospitals. Patients who are 20-80 years old, diagnosed as having Inflammatory Bowel Disease(IBD) and who are planned to start thiopurines for the…
- Trial name
- NCT03719118
- Testing
- genotyping for three genes (TPMT, NUDT15 and FTO), non-genotyping
- Where
- 5 sites in South Korea
- Volunteers
- 215 people
- Sponsor
- Yonsei University
Abnormal Hematopoiesis, Allogenic Disease
Graft-versus-host Disease Associated Myelosuppression
The objective is to measure the frequency, functionality and phenotype of bone marrow-derived mesenchymal stromal cells in patients after allogeneic hematopoietic stem cell transplantation.
- Conditions
- Abnormal Hematopoiesis, Allogenic Disease, Graft vs Host Disease
- Trial name
- NCT02829216
- Where
- Germany
- Volunteers
- 50 people
- Sponsor
- Technische Universität Dresden
Myelosuppression
Profonycia - Honey for Improving Quality of Patient's Life Receiving Chemotherapy
Myelosuppression (bone marrow suppression) is the most important toxic side effect of the majority of chemotherapeutic agents and typically is the dose limiting factor.
- Trial name
- NCT00524797
- Testing
- Profonycia
- Where
- 2 sites in Israel
- Volunteers
- 50 people
- Sponsor
- Ziv Hospital
Prevention of Chemotherapy-induced Myelosuppression
A Study of ALRN-6924 for Protection of Chemotherapy-Induced Side Effects in Patients With TP53-Mutant Breast Cancer
This is a Phase 1b open-label, single arm, multicenter, study of ALRN-6924 as a chemoprotection agent in patients with TP53-mutated HER2- breast cancer (stages IIa to IIIb) receiving neoadjuvant or adjuvant chemotherapy with…
- Trial name
- NCT05622058
- Testing
- ALRN-6924, TAC (doxorubicin 50 mg/m2; cyclophosphamide 500 mg/m2; docetaxel 75 mg/m2)
- Where
- 14 sites in United States, Bosnia and Herzegovina and 2 more
- Volunteers
- 6 people
- Sponsor
- Aileron Therapeutics, Inc.
Unspecified Adult Solid Tumor, Protocol Specific, Neutropenia
BMS-247550 in Treating Patients With Cancers That Have Not Responded to Previous Therapy
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase I trial to study the effectiveness of BMS-247550 in treating patients who have cancers that…
- Trial name
- NCT00020371
- Testing
- BMS-247550, filgrastim
- Where
- United States
- Sponsor
- National Cancer Institute (NCI)
Osteosarcoma, Bone Metastases
A Dose Finding Study of CycloSam® Combined With External Beam Radiotherapy
This is a dose finding study of a novel radiopharmaceutical agent, 153Sm-DOTMP. It will be studied alone and then in combination with external beam radiotherapy. The study design includes six cohorts, Levels 1-6.
- Trial name
- NCT03612466
- Testing
- 153Sm-DOTMP, External beam radiotherapy., Calcium Carbonate
- Where
- United States
- Sponsor
- Albert Einstein College of Medicine
Nasopharyngeal Carcinoma (NPC), Myelosuppression
Dynamic Risk Prediction of Severe Myelosuppression in Nasopharyngeal Carcinoma
This multicenter, prospective, observational cohort study aims to evaluate a previously developed dynamic risk prediction model for severe treatment-related myelosuppression in patients with nasopharyngeal carcinoma receiving…
- Trial name
- NCT07819656
- Where
- China
- Volunteers
- 1,782 people
- Sponsor
- Nanfang Hospital, Southern Medical University
Myelosuppression
Trilaciclib Prevents Myelosuppression With Chemoradiotherapy
To evaluate the protective effect of Trilaciclib on myelosuppression in patients with limited-stage small cell lung cancer associated with concurrent chemoradiotherapy and discuss the effect of gut microbiota changes on…
- Trial name
- NCT06490081
- Testing
- Trilaciclib
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Breast Cancer
Study of the P16 Gene as a Predictor of Myelosuppression in Breast Cancer Patients
The primary purpose of this study is to measure the association between baseline expression of the senescence effector protein p16INK4a and myelosuppression due to chemotherapy in patients with breast cancer.
- Trial name
- NCT01305954
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- UNC Lineberger Comprehensive Cancer Center